Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
180 Life Sciences ( (ATNF) ) has shared an update.
On February 5, 2025, 180 Life Sciences Corp. amended its Separation and Release Agreement with former CEO James N. Woody, replacing a contingent $50,000 bonus with $60,000 in restricted common stock, which includes voting and sale restrictions. Additionally, on February 4, 2025, the company’s Board appointed Ryan Smith as Lead Independent Director and Blair Jordan as Chief Executive Officer, with Jordan’s annual compensation increased to $240,000, reflecting strategic leadership changes.
More about 180 Life Sciences
180 Life Sciences Corp. operates in the biotechnology industry, focusing on the development of therapeutics for inflammatory diseases, fibrosis, and pain. The company is engaged in the research and development of novel drugs and has a notable presence in the biotechnology market.
YTD Price Performance: -19.77%
Average Trading Volume: 450,344
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.38M
For detailed information about ATNF stock, go to TipRanks’ Stock Analysis page.